A5079310177- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- CNS Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- Acute Lymphoblastic Leukemia research
- Vascular Malformations and Hemangiomas
- Renal cell carcinoma treatment
- Systemic Sclerosis and Related Diseases
- Histiocytic Disorders and Treatments
- Multiple Sclerosis Research Studies
- Viral-associated cancers and disorders
- Cancer Genomics and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Hepatocellular Carcinoma Treatment and Prognosis
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
Sylvester Comprehensive Cancer Center
2024
Fred Hutch Cancer Center
2024
City Of Hope National Medical Center
2024
Moffitt Cancer Center
2024
Prisma Health
2024
City of Hope
2024
The University of Texas Health Science Center at San Antonio
2024
Cornell University
2024
West Michigan Cancer Center
2023
Hematology Oncology Consultants
2011-2023
BackgroundIncorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However, increases toxic effects adults, more than half patients who receive drug undergo consolidative radiation, relapse remains a challenge. Programmed death 1 blockade is effective lymphoma, including preliminary studies involving previously untreated patients.MethodsWe conducted phase 3, multicenter, open-label, randomized trial...
Background: The addition of BV to initial chemotherapy improves outcomes in adult and pediatric patients (pts) with AS HL. However, frontline adds toxicity, most pts receive radiation therapy (RT), 7%–20% still develop relapsed/refractory (RR) PD-1 pathway is central the pathogenesis HL blockade effective RR cooperative groups National Clinical Trials Network (NCTN) conducted randomized, phase 3 S1826 trial evaluate N-AVD versus BV-AVD newly diagnosed Methods: Eligible were ≥12 years (y)...
Abstract Purpose: We hypothesized that resistance to hypomethylating agents (HMA) among patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) would be overcome by combining a programmed death-ligand 1 antibody an HMA. Patients Methods: conducted Phase I/II, multicenter clinical trial for MDS not achieving International Working Group response after at least 4 cycles of HMA (“refractory”) or progressing (“relapsed”) 3+ higher risk the revised Prognostic...
High-dose chemotherapy with autologous hematopoietic progenitor cell (HPC) transplantation improves survival for patients multiple myeloma (MM); however, most develop recurrent disease after undergoing transplantation, and new treatment approaches are needed. The objective of this retrospective review HPC MM was to evaluate the impact conditioning regimens posttransplantation therapy on survival.The authors reviewed 112 who received grafts at their institution. Between June 1992 August 2001,...
Hydration and urinary alkalinization are essential for reducing renal dysfunction with high dose methotrexate (HDMTX). This report presents an analysis of institutional methods used to achieve adequate output patients receiving single agent HDMTX. Renal metabolic parameters tolerance were examined.Medical records adult HDMTX during the calendar years 2008-2009 retrospectively reviewed determine time urine pH > 7. Number hospital days, bicarbonate dose, ordered hydration rate, output,...
Abstract BACKGROUND. Matrix metalloproteinases (MMPs) are overexpressed in Kaposi sarcoma (KS). The safety and efficacy of a novel, orally bioavailable MMP inhibitor, BMS‐275291, was evaluated patients with human immunodeficiency virus‐associated KS the correlation between changes percentage apoptotic cells tumor biopsies response explored. METHODS. Cohorts 6 were to be treated BMS‐275291. initial cohort received 1200 mg once day; subsequent doses escalated 600 twice daily daily, or...
Purpose Grade ≥3 adverse effects prolong hospitalization and reduce chemotherapy dose intensity. The purpose of this study was to evaluate the rate severity high-dose methotrexate-related acute kidney injury analyze its effect on hospital length stay relative Methods This a retrospective cohort analysis. Patients receiving ≥1 methotrexate were analyzed for stay. ≥6 cycles induction therapy included in analysis Chi squared used determine differences between dichotomous data; Student's t-test...
<div>AbstractPurpose:<p>We hypothesized that resistance to hypomethylating agents (HMA) among patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) would be overcome by combining a programmed death-ligand 1 antibody an HMA.</p>Patients Methods:<p>We conducted Phase I/II, multicenter clinical trial for MDS not achieving International Working Group response after at least 4 cycles of HMA (“refractory”) or progressing (“relapsed”) 3+...
<div>AbstractPurpose:<p>We hypothesized that resistance to hypomethylating agents (HMA) among patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) would be overcome by combining a programmed death-ligand 1 antibody an HMA.</p>Patients Methods:<p>We conducted Phase I/II, multicenter clinical trial for MDS not achieving International Working Group response after at least 4 cycles of HMA (“refractory”) or progressing (“relapsed”) 3+...
<p>A& B. Frequency (A) and intensity (B) of PD-1+ CD8+ T cells by gender) before (PRE), after second treatment cycle (C2D1 or C2D8; EARLY), third fourth (C4D1, C4D8 C5D1; LATE). cell expressing CD39 (C) CD69 (D). F: females, M: males</p>
<p>A& B. Frequency (A) and intensity (B) of PD-1+ CD8+ T cells by gender) before (PRE), after second treatment cycle (C2D1 or C2D8; EARLY), third fourth (C4D1, C4D8 C5D1; LATE). cell expressing CD39 (C) CD69 (D). F: females, M: males</p>
<p>A. Gating strategy applied on PBMCs samples evaluated by flow cytometry. CD8+ T cell memory was defined based the expression of CD45RA and CCR7 (CD197). Cell surface phenotype (PD-1, CD39, CD69) intracellular activation (Ki-67) markers were quantified effector (TEFF) indicated gates. B, naïve cells in long-and short-survivors before after treatment. C, Representative cytometry plots showing PBMC from a short survivor. PD-1+ Ki-67+ compared treatment.</p>
<p>Median overall survival was longer among patients whose T cells harbored ASXL1 mutations (green) than for those without the mutation (red) or with only myeloid (blue), but status not associated in a univariate analysis by logrank test (p=0.11). In multivariate using Cox proportional model and adjusted age at study entry, gender, diagnosis, number of prior treatment regimens, significantly (p=0.001 based on likelihood ratio test).</p>
<p>A. Gating strategy applied for flow cytometry analysis of NK cell panel. Phenotype (CD56dim CD16+ ) activation was quantified using expression surface markers CD69, CD107a, CD45RA, and CD45RO based on the indicated gates. B. frequency before after treatment analyzed in PBMCs from 18 patient samples grouped according long-and short-survivors. C. Frequency cells expressing CD45RA measured short-and long-survival groups treatment.</p>
<p>Median overall survival was longer among patients whose T cells harbored ASXL1 mutations (green) than for those without the mutation (red) or with only myeloid (blue), but status not associated in a univariate analysis by logrank test (p=0.11). In multivariate using Cox proportional model and adjusted age at study entry, gender, diagnosis, number of prior treatment regimens, significantly (p=0.001 based on likelihood ratio test).</p>
<p>A. Gating strategy applied for flow cytometry analysis of NK cell panel. Phenotype (CD56dim CD16+ ) activation was quantified using expression surface markers CD69, CD107a, CD45RA, and CD45RO based on the indicated gates. B. frequency before after treatment analyzed in PBMCs from 18 patient samples grouped according long-and short-survivors. C. Frequency cells expressing CD45RA measured short-and long-survival groups treatment.</p>
<p>Isolation and DNA extraction of bone marrow cell populations; Targeted sequencing; Peripheral blood mononuclear (PBMC) staining flow cytometry analysis</p>
<p>Isolation and DNA extraction of bone marrow cell populations; Targeted sequencing; Peripheral blood mononuclear (PBMC) staining flow cytometry analysis</p>